Table 1.
Comparison of Patients with Chronic GVHD and Controls for Differences in Age, Sex, Donor Type, Donor Source, Acute GVHD, GVHD Prophylaxis and Concurrent Steroids
| Early controls (N=18) |
Early cGVHD (N=33) |
Difference (95% CI) |
Late controls (N=11) |
Late cGVHD (N=11) |
|
|---|---|---|---|---|---|
| Age: | |||||
| Median (Range) | 9.0(1.3,20.7) | 11.3(2.0,21.0) | 7.3(1.2,15.4) | 13.5(3.2,21.8) | |
| Mean (SD) | 9.7(6.0) | 12.0(5.7) | 7.0(4.8) | 13.2(5.5) | |
| Sex: | |||||
| Male | 12 (67%) | 23 (70%) | 7 (64%) | 8 (73%) | |
| Female | 6 (33%) | 10 (30%) | 4 (36%) | 3 (27%) | |
| Donor Source: | |||||
| Bone marrow | 11 (61%) | 13 (39%) | 21.7%(-6,49) | 7 (64%) | 7 (64%) |
| Peripheral blood | 4 (22%) | 14 (42%) | 20.2%(-45,5) | 2 (18%) | 2 (18%) |
| Umbilical cord blood |
3 (17%) | 6 (18%) | 2 (18%) | 2 (18%) | |
| Donor type: | |||||
| Sibling | 13 (72%) | 15 (45%) | 27%(0,54) | 7 (64%) | 5 (45%) |
| Unrelated | 5 (28%) | 18 (55%) | 27%(-53,0) | 4 (36%) | 6 (55%) |
| Acute GVHD: | |||||
| Yes | 6 (33%) | 20 (61%) | 27%(-54,0) | 4 (36%) | 6 (55%) |
| No | 12 (66%) | 13 (39%) | 27%(0,54) | 7 (64%) | 5 (45%) |
|
GVHD prophylaxis: |
|||||
| CSA | 14 (78%) | 26 (79%) | 10 (91%) | 9 (82%) | |
| MTX | 13 (72%) | 22 (67%) | 8 (73%) | 6 (55%) | |
| Steroids | 6 (33%) | 8 (24%) | 4 (36%) | 3 (27%) | |
| Tacrolimus | 6 (33%) | 7 (21%) | 3 (27%) | 2 (18%) | |
| MMF | - | 2 (6%) | - | - | |
| ATG | - | 2 (6%) | - | - | |
|
On Prednisone or equivalent (≤ 2 mg/kg/day) at study entry: |
|||||
| Yes | 8 (44%) | 16 (48%) | 5 (45%) | 3 (27%) | |
| No | 10 (56%) | 17 (48%) | 6 (55%) | 8 (73%) | |